The real world cost and health resource utilization associated to manic episodes: The MANACOR study

Introduction: Bipolar disorder is a relapsing-remitting condition affecting approximately 1-2% of the population. Even when the treatments available are effective, relapses are still very frequent. Therefore, the burden and cost associated to every new episode of the disorder have relevant implications in public health. The main objective of this study was to estimate the associated health resource consumption and direct costs of manic episodes in a real world clinical setting, taking into consideration clinical variables. Methods: Bipolar I disorder patients who recently presented an acute manic episode based on DSM-IV criteria were consecutively included. Sociodemographic variables were retrospectively collected and during the 6 following months clinical variables were prospectively assessed (YMRS, HDRS-17,FAST and CGI-BP-M). The health resource consumption and associate cost were estimated based on hospitalization days, pharmacological treatment, emergency department and outpatient consultations. Results: One hundred sixty-nine patients patients from 4 different university hospitals in Catalonia (Spain) were included. The mean direct cost of the manic episodes was (sic)4,771. The 77% ((sic)3,651) was attributable to hospitalization costs while 14% ((sic)684) was related to pharmacological treatment, 8% ((sic)386) to outpatient visits and only 1% ((sic)50) to emergency room visits. The hospitalization days were the main cost driver. An initial FAST score >41 significantly predicted a higher direct cost. Conclusions: Our results show the high cost and burden associated with BD and the need to design more cost-efficient strategies in the prevention and management of manic relapses in order to avoid hospital admissions. Poor baseline functioning predicted high costs, indicating the importance of functional assessment in bipolar disorder. (C) 2014 SEP y SEPB. Published by Elsevier Espana, S.L.U. All rights reserved.